ClinicalTrials.gg
RecruitingNCT04985344PPPUpdated Aug 28, 2023

Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol

A Phase 3 interventional study of Propranolol Oral Product and Placebo in PTSD, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 7 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-08-28.

Sponsored by University Hospital, Toulouse · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
7 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies testing propranolol in Stress Disorders, Post-Traumatic — 2 open to participants now, 2 under way, 2 of them phase 3. Propranolol · Stress Disorders, Post-Traumatic.

Planned enrollment
2nd of 24
92 · median 44
Started
2023
with 2 others
Phase 3
3 of 24
2 open now
Registered
19th of 24
by date
Lead sponsor
4 of 24
University Hospital, Toulouse

Among the 24 studies testing propranolol in Stress Disorders, Post-Traumatic, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 19th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

2 of the 24 studies testing propranolol in Stress Disorders, Post-Traumatic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About propranolol

Propranolol: first FDA approval 1967 (INDERAL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 7 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing propranolol in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

By age 18, roughly 8% of traumatized youth have met criteria for a diagnosis of PTSD, with numbers rising up to 40% in cases of sexual abuse and assault. To date there is no empirical support for the use of psychopharmacological interventions as treatment of pediatric PTSD. Trauma-focused psychotherapeutic/TFP approaches should be favored in childhood PTSD. However, when compared to active control conditions, TFP produced a mean effect size on child and adolescents population (g=0.83). Moreover, in therapies with a substantial exposure component, the intense and lengthy reexperiencing of the traumatic event results in a substantial proportion of participants dropping out.

The reactivation of a previously consolidated memory can make it labile, subsequently requiring a re-stabilization of it called reconsolidation of the memory.

Acting on these reconsolidation processes makes possible to interfere with the subsequent storage of this memory.

Read the detailed description

By age 18, roughly 8% of traumatized youth have met criteria for a diagnosis of PTSD, with numbers rising up to 40% in cases of sexual abuse and assault. To date there is no empirical support for the use of psychopharmacological interventions as treatment of pediatric PTSD. Trauma-focused psychotherapeutic/TFP approaches should be favored in childhood PTSD. However, when compared to active control conditions, TFP produced a mean effect size on child and adolescents population (g=0.83). Moreover, in therapies with a substantial exposure component, the intense and lengthy reexperiencing of the traumatic event results in a substantial proportion of participants dropping out.

The reactivation of a previously consolidated memory can make it labile, subsequently requiring a re-stabilization of it called reconsolidation of the memory.

Acting on these reconsolidation processes makes possible to interfere with the subsequent storage of this memory.

The combination of the targeted reactivation of the traumatic memory and the intake of an agent that decreases the reconsolidation can thus disrupt the recall of unwanted memories and thus serve as a treatment for people suffering from traumatic memories, such as in PTSD.

Since stimulation of β-noradrenergic receptors facilitates the consolidation of memories as well as their re-consolidation, an antagonist of these receptors, propranolol, has generated considerable interest as a treatment to alleviate emotional and traumatic memories in individuals with PTSD.

In adults diagnosed with long-standing PTSD two 6-week, double-blind, placebocontrolled, randomised clinical trials, one in 60 subjects and the other in 67 have shown promising results. PTSD participants who actively recalled their traumatic event under the influence of propranolol once a week for up to 6 weeks showed a substantial decrease in symptom ratings compared with placebo. Thus, all of this data led the team to propose a comparable design study in children with PTSD

03

Conditions studied

  • PTSD

Keywords

  • PTSD
  • traumatic memory reactivation
  • pediatric
  • Propranolol
  • Post-traumatic stress disorder
04

Who can participate

Ages eligible
7 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 7-12 years
  • CPTS-RI total score ≥40
  • Primary diagnosis of PTSD (6 months or more after the traumatic event)
  • Heart rate ≥ 55 bpm
  • Systolic blood pressure ≥ 95 mm Hg
  • Affiliation to a social security scheme
  • Written consent signed by the parents/holders of parental authority and the investigator
  • Acceptance of the protocol by the child-Child and Parents/Holders of parental authority fluent in French

Exclusion criteria

Exclusion Criteria:

  • Age\<7 years or ≥13 years
  • Children whose parents have been deprived of their authority
  • to propranolol (cardiogenic shock, sinus bradycardia, hypotension (\< fifth percentile oscillometric or \<2SD) (Banker et al., 2016 - see APPENDIX 1), greater than first-degree heart block, heart failure, bronchial asthma and to propranolol hydrochloride)
  • Concurrent medication with possible interactions with propranolol (cf 8.2)
  • Concurrent psychotropic drugs that have been shown to be effective in improving symptoms of PTSD (Antidepressants, atypical antipsychotics, mood stabilizers)
  • Concurrent psychotherapy (>1 structured session/month declared by the clinician who follows the child)
  • Current active psychosis, anorexia nervosa, bulimia nervosa, binge-eating disorder, attention-deficit hyperactivity disorder, autism spectrum disorder
  • Children with psoriasis
  • Children with a predisposition to hypoglycemia
  • Obsessive-compulsive disorders
  • Bipolar Disorders
  • Mental retardation,
  • Traumatic brain injury (loss of consciousness > 10 minutes)
  • Currently treated with a bradycardic drug
  • Concurrent participation to another interventional study
  • Renal or Hepatic Impairment
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Propranolol

    Patient will receive oral propranolol

    Drug: Propranolol Oral Product · Other: memory reactivation

  • Placebo comparator
    Placebo

    Patient will receive oral placebo

    Drug: Placebo · Other: memory reactivation

Interventions

  • DrugPropranololStudies of PropranololPropranolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.

    Also known as: Propranolol

  • DrugPlacebo

    Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.

  • Othermemory reactivation

    90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.

06

What researchers measure

Primary outcomes

  1. Child Post-Traumatic Stress Reaction Index/CPTS-RI

    The main evaluation criterion will be the difference between the Child Post-Traumatic Stress Reaction Index/CPTS-RI total score administered at week 8 and week 0. The CPTS-RI is a scale comprised of 20 Likert-type items, intended for children from 6 to 16 years, which evaluates the symptoms of PTSD after exposure to various traumatic events. Each item frequency is rated on a 5-point scale, from never (=0) to almost always (=4). The global score consists of the sum of the 20 items and ranges from 0 to 80, with higher scores indicating higher PTSD symptom severity. The time required for completion of the scale is 15-20 min. A total score of 12-24 is associated with a mild level of PTSD, from 25-39 with a moderate level, from 40-59 with a severe level, and ≥60 with a very severe level.

    Time frame: week 8

Secondary outcomes

  1. Child Post-Traumatic Stress Reaction - Week 32 Index/CPTS-RI

    The difference between the Child Post-Traumatic Stress Reaction Index/CPTS-RI total score at week 32 and week 8 . The CPTS-RI is a scale comprised of 20 Likert-type items, intended for children from 6 to 16 years, which evaluates the symptoms of PTSD after exposure to various traumatic events. Each item frequency is rated on a 5-point scale, from never (=0) to almost always (=4). The global score consists of the sum of the 20 items and ranges from 0 to 80, with higher scores indicating higher PTSD symptom severity. The time required for completion of the scale is 15-20 min. A total score of 12-24 is associated with a mild level of PTSD, from 25-39 with a moderate level, from 40-59 with a severe level, and ≥60 with a very severe level.

    Time frame: week 32

  2. Child Post-Traumatic Stress Reaction - Week 60 Index/CPTS-RI

    The difference between the Child Post-Traumatic Stress Reaction Index/CPTS-RI total score administered at week 60 and week 8. The CPTS-RI is a scale comprised of 20 Likert-type items, intended for children from 6 to 16 years, which evaluates the symptoms of PTSD after exposure to various traumatic events. Each item frequency is rated on a 5-point scale, from never (=0) to almost always (=4). The global score consists of the sum of the 20 items and ranges from 0 to 80, with higher scores indicating higher PTSD symptom severity. The time required for completion of the scale is 15-20 min. A total score of 12-24 is associated with a mild level of PTSD, from 25-39 with a moderate level, from 40-59 with a severe level, and ≥60 with a very severe level.

    Time frame: week 60

  3. Child PTSD Checklist-Child version/CPC-C total score

    The difference between the Child PTSD Checklist-Child version/CPC-C total score administered at week 8 and week 0 on items 14-34. The CPC-C includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment. It is free in the public domain. For scoring the CPC-C 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion. Items 14-34 are PTSD symptom items.

    Time frame: Week 8

  4. Child PTSD Checklist-Child version/CPC-C total score - Week 32

    The difference between the Child PTSD Checklist-Child version/CPC-C total score administered at week 8 and week 32 on items 14-34. The CPC-C includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment. It is free in the public domain. For scoring the CPC-C 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion. Items 14-34 are PTSD symptom items.

    Time frame: Week 32

  5. Child PTSD Checklist-Child version/CPC-C total score - Week 60

    The difference between the Child PTSD Checklist-Child version/CPC-C total score administered at week 8 and week 60 on items 14-34. The CPC-C includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment. It is free in the public domain. For scoring the CPC-C 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion. Items 14-34 are PTSD symptom items.

    Time frame: Week 60

  6. Child PTSD Checklist-Parent version/CPC-P total score - Week 32

    The difference between the Child PTSD Checklist-Parent version/CPC-P total score administered at week 8 and week 32 on items 14-34 (PTSD symptom items). The CPC-P includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment. It is free in the public domain. For scoring the CPC-P, 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion. Items 14-34 are PTSD symptom items.

    Time frame: Week 32

  7. Child PTSD Checklist-Parent version/CPC-P total score - Week 60

    The difference between the Child PTSD Checklist-Parent version/CPC-P total score administered at week 8 and week 60 on items 14-34 (PTSD symptom items). The CPC-P includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment. It is free in the public domain. For scoring the CPC-P, 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion. Items 14-34 are PTSD symptom items.

    Time frame: Week 60

  8. Child PTSD Checklist-Parent version/CPC-P total score

    The difference between the Child PTSD Checklist-Parent version/CPC-P total score administered at week 8 and week 0 on items 14-34 (PTSD symptom items). The CPC-P includes a traumatic events page, 21 PTSD symptoms and 6 items of functional impairment. It is free in the public domain. For scoring the CPC-P, 7-18 years (Version May 23, 2014.), the Traumatic Events page (items 1-13) is important to include before administering the symptom portion. Items 14-34 are PTSD symptom items.

    Time frame: Week 8

  9. Kiddie-SADS-Present and Lifetime Version DSM-5/K-SADS-PL-DSM5

    The percentage of children without a current diagnosis of PTSD assessing with Kiddie-SADS-Present and Lifetime Version DSM-5/K-SADS-PL-DSM5. The K-SADS-PL-DSM5 (November 2016) is a semi-structured diagnostic interview designed to collect information from the child or adolescent as well as their parents or other informants.

    Time frame: week 8

  10. Current diagnosis of PTSD at Week 32

    The percentage of children without a current diagnosis of PTSD assessing with Kiddie-SADS-Present and Lifetime Version DSM-5/K-SADS-PL-DSM5. The K-SADS-PL-DSM5 (November 2016) is a semi-structured diagnostic interview designed to collect information from the child or adolescent as well as their parents or other informants.

    Time frame: week 32

  11. Children Depression Inventory/CDI total score

    The difference between the Children Depression Inventory/CDI total score administered at week 8 and week 0. The CDI is comprised of 27 items assessing self-reported symptoms of depression in children and adolescents 7-17 years of age.

    Time frame: week 8

  12. Children Depression Inventory/CDI total score - Week 32

    The difference between the Children Depression Inventory/CDI total score administered at week 8 and week 32. The CDI is comprised of 27 items assessing self-reported symptoms of depression in children and adolescents 7-17 years of age.

    Time frame: week 32

  13. Children Depression Inventory/CDI total score - Week 60

    The difference between the Children Depression Inventory/CDI total score administered at week 8 and week 60. The CDI is comprised of 27 items assessing self-reported symptoms of depression in children and adolescents 7-17 years of age.

    Time frame: week 60

  14. Children's Sleep Habits Questionnaire/CSHQ Parent version total score

    The difference between the Children's Sleep Habits Questionnaire/CSHQ Parent version total score administered at week 8 and week 0.The CSHQ was designed by clinical researchers at Brown University for children aged 4 through 12 years, to screen for the most common sleep problems in that age group.The first column 'of responses are scored: Usually=3, Sometimes=2, Rarely=1 for the entire questionnaire (except for the R=reversed items, which are considered to be "desirable" sleep behaviors, and thus scored in the opposite direction)

    Time frame: week 8

  15. Children's Sleep Habits Questionnaire/CSHQ Parent version total score - Week 32

    The difference between the Children's Sleep Habits Questionnaire/CSHQ Parent version total score administered at week 8 and week 32.The CSHQ was designed by clinical researchers at Brown University for children aged 4 through 12 years, to screen for the most common sleep problems in that age group.The first column 'of responses are scored: Usually=3, Sometimes=2, Rarely=1 for the entire questionnaire (except for the R=reversed items, which are considered to be "desirable" sleep behaviors, and thus scored in the opposite direction)

    Time frame: week 32

  16. Children's Sleep Habits Questionnaire/CSHQ Parent version total score - Week 60

    The difference between the Children's Sleep Habits Questionnaire/CSHQ Parent version total score administered at week 8 and week 60.The CSHQ was designed by clinical researchers at Brown University for children aged 4 through 12 years, to screen for the most common sleep problems in that age group.The first column 'of responses are scored: Usually=3, Sometimes=2, Rarely=1 for the entire questionnaire (except for the R=reversed items, which are considered to be "desirable" sleep behaviors, and thus scored in the opposite direction)

    Time frame: week 60

  17. Comorbidity of other mental disorders

    Using the K-SADS-PL DSM-5

    Time frame: week 8

  18. Corsi Blocks task

    The difference between the Corsi blocks task administered at week 0 and at week 8. The Corsi Blocks task assesses the visuospatial component of working memory but uses various cognitive processes. The subject needs to reproduce, in the same or reverse order, a sequence of pointing movements to different cubes shown by the rater

    Time frame: week 8

  19. CGAS Children's Global Assessment Scale total score

    The difference between the CGAS Children's Global Assessment Scale total score administered at week 8 and the score administered at week 32. The Childrens Global Assessment Scale (CGAS) is a measure developed by Schaffer and colleagues at the Department of Psychiatry, Columbia University to provide a global measure of level of functioning in children and adolescents. The measure provides a single global rating only, on scale of 0-100.

    Time frame: week 32

  20. CGAS Children's Global Assessment Scale total score - Week 60

    The difference between the CGAS Children's Global Assessment Scale total score administered at week 8 and the score administered at week 60. The Childrens Global Assessment Scale (CGAS) is a measure developed by Schaffer and colleagues at the Department of Psychiatry, Columbia University to provide a global measure of level of functioning in children and adolescents. The measure provides a single global rating only, on scale of 0-100.

    Time frame: week 60

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Olliac B, Birmes P, Bui E, Allenou C, Brunet A, Claudet I, Sales de Gauzy J, Grandjean H, Raynaud JP. Validation of the French version of the Child Post-Traumatic Stress Reaction Index: psychometric properties in French speaking school-aged children. PLoS One. 2014 Dec 2;9(12):e112603. doi: 10.1371/journal.pone.0112603. eCollection 2014. PubMed 25460912 ↗
  • Roullet P, Vaiva G, Very E, Bourcier A, Yrondi A, Dupuch L, Lamy P, Thalamas C, Jasse L, El Hage W, Birmes P. Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial. Neuropsychopharmacology. 2021 Aug;46(9):1643-1649. doi: 10.1038/s41386-021-00984-w. Epub 2021 Feb 21. PubMed 33612830 ↗
  • Birmes P, Raynaud JP, Daubisse L, Brunet A, Arbus C, Klein R, Cailhol L, Allenou C, Hazane F, Grandjean H, Schmitt L. Children's enduring PTSD symptoms are related to their family's adaptability and cohesion. Community Ment Health J. 2009 Aug;45(4):290-9. doi: 10.1007/s10597-008-9166-3. Epub 2009 Jul 21. PubMed 19621258 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Sep 2027, 55 months after the start.

Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 55 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2021
First posted
Aug 2, 2021
StartActual
Feb 1, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Aug 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04985344
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Feb 1, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 28, 2023

Study contacts

Philippe Birmes, PH
Contact
birmes.p@chu-toulouse.fr
05 34 55 75 00 ext. +33
Philippe Birmes, PH
principal investigator · Toulouse University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propranolol

Start the discussion